Kannan Rangaramanujam

KANNAN RANGARAMANUJAM, MS, PhD, the Arnall Patz Distinguished Professor, is the co-director of The Center for Nanomedicine at the Johns Hopkins Wilmer Eye Institute and a leading authority on nanotechnology-based targeted drug delivery systems. He also holds joint appointments at the Johns Hopkins University Whiting School of Engineering in the Departments of Chemical and Biomolecular Engineering and Materials Science and Engineering, as well as at the Kennedy Krieger Institute.

Dr. Rangaramanujam received his PhD in chemical engineering from the California Institute of Technology and completed a postdoctoral fellowship at the University of Minnesota.

Primarily funded by the National Institutes of Health, the interdisciplinary translational research program he initiated focuses on nanotechnology-based approaches for targeted treatment of neuroinflammation.

His team’s systemic, targeted drug delivery strategies for a variety of central nervous system and ocular disorders have been validated in many preclinical models of ocular and brain disorders, including age-related macular degeneration (AMD), diabetic retinopathy, dry eye, retinitis pigmentosa, cerebral palsy, leukodystrophies, and glioblastoma.

An author of many patents and more than 85 peer-reviewed publications, Dr. Rangaramanujam has received both the National Science Foundation Faculty Early Career Development (CAREER) and the Unilever awards.

In addition, he serves as the chief technology officer of Ashvattha Therapeutics Inc. and Orpheris Inc., two companies in the process of translating his team’s patented dendrimer technologies for unmet clinical needs.